Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine

Detalhes bibliográficos
Autor(a) principal: Magalhães, Elza
Data de Publicação: 2010
Outros Autores: Menezes, Carla, Cardeal, Mauricio, Melo, Ailton de Souza
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFBA
Texto Completo: http://www.repositorio.ufba.br/ri/handle/ri/5767
Resumo: Acesso restrito: Texto completo. p. 463-466
id UFBA-2_19f2120a01fd9ad4250acc44cde43089
oai_identifier_str oai:repositorio.ufba.br:ri/5767
network_acronym_str UFBA-2
network_name_str Repositório Institucional da UFBA
repository_id_str 1932
spelling Magalhães, ElzaMenezes, CarlaCardeal, MauricioMelo, Ailton de SouzaMagalhães, ElzaMenezes, CarlaCardeal, MauricioMelo, Ailton de Souza2012-05-03T19:21:48Z20100303-8467http://www.repositorio.ufba.br/ri/handle/ri/5767v. 112, n. 6Acesso restrito: Texto completo. p. 463-466Objective: To compare the effects of botulinum toxin type A with those of amitriptyline on the treatment of chronic daily migraines. Methods: Chronic migraine sufferers were randomized into two groups and treated with 25 or 50 mg/day of amitriptyline or 250U of botulinum toxin type A. A reduction of at least 50% in the number of pain episodes, in the intensity of pain, and in the number of drug doses for pain and reports of improvement by the patient or by the examiner were the main endpoints. Results: Seventy-two subjects were enrolled in the study. A reduction of at least 50% in the number of days of pain was recorded in 67.8% of the patients in the BTX-A group and 72% (n = 23) of the patients in the AM group (p = 0.78; RR = 0.94; CI = 0.11–8). The reduction in the intensity of pain, as assessed using the visual analogical scale, was 50% in the BXT-A group and 55.6% in the AM group (p = 0.79; RR = 1.11; CI = 0.32–3.8). The reduction in the number of pain drug doses was 77% for the toxin group and 71% for the amitriptyline group (p = 0.76; RR = 0.92; CI = 0.45–1.88). Conclusions: Botulinum toxin type A was as effective as amitriptyline for the prophylactic treatment of chronic daily migraines.Submitted by JURANDI DE SOUZA SILVA (jssufba@hotmail.com) on 2012-05-03T19:21:48Z No. of bitstreams: 1 __ac.els-cdn.com_S030384...f27d3c08fc3ed10c3efbf15a99171.pdf: 96186 bytes, checksum: d7e81783ccc1abefedcc2130a48ec01f (MD5)Made available in DSpace on 2012-05-03T19:21:48Z (GMT). No. of bitstreams: 1 __ac.els-cdn.com_S030384...f27d3c08fc3ed10c3efbf15a99171.pdf: 96186 bytes, checksum: d7e81783ccc1abefedcc2130a48ec01f (MD5) Previous issue date: 2010DOI: 10.1016/j.clineuro.2010.02.004reponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBAChronic migraineAmitriptylineBotulinum toxinBotulinum toxin type A versus amitriptyline for the treatment of chronic daily migraineClinical Neurology and Neurosurgeryinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article10000-01-01enginfo:eu-repo/semantics/openAccessORIGINAL__ac.els-cdn.com_S030384...f27d3c08fc3ed10c3efbf15a99171.pdf__ac.els-cdn.com_S030384...f27d3c08fc3ed10c3efbf15a99171.pdfapplication/pdf96186https://repositorio.ufba.br/bitstream/ri/5767/1/__ac.els-cdn.com_S030384...f27d3c08fc3ed10c3efbf15a99171.pdfd7e81783ccc1abefedcc2130a48ec01fMD51LICENSElicense.txtlicense.txttext/plain1762https://repositorio.ufba.br/bitstream/ri/5767/2/license.txt1b89a9a0548218172d7c829f87a0eab9MD52TEXT__ac.els-cdn.com_S030384...f27d3c08fc3ed10c3efbf15a99171.pdf.txt__ac.els-cdn.com_S030384...f27d3c08fc3ed10c3efbf15a99171.pdf.txtExtracted texttext/plain19009https://repositorio.ufba.br/bitstream/ri/5767/3/__ac.els-cdn.com_S030384...f27d3c08fc3ed10c3efbf15a99171.pdf.txt152139dc1a4ca8b672643bed94a83466MD53ri/57672022-07-05 14:03:20.925oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-07-05T17:03:20Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false
dc.title.pt_BR.fl_str_mv Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine
dc.title.alternative.pt_BR.fl_str_mv Clinical Neurology and Neurosurgery
title Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine
spellingShingle Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine
Magalhães, Elza
Chronic migraine
Amitriptyline
Botulinum toxin
title_short Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine
title_full Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine
title_fullStr Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine
title_full_unstemmed Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine
title_sort Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine
author Magalhães, Elza
author_facet Magalhães, Elza
Menezes, Carla
Cardeal, Mauricio
Melo, Ailton de Souza
author_role author
author2 Menezes, Carla
Cardeal, Mauricio
Melo, Ailton de Souza
author2_role author
author
author
dc.contributor.author.fl_str_mv Magalhães, Elza
Menezes, Carla
Cardeal, Mauricio
Melo, Ailton de Souza
Magalhães, Elza
Menezes, Carla
Cardeal, Mauricio
Melo, Ailton de Souza
dc.subject.por.fl_str_mv Chronic migraine
Amitriptyline
Botulinum toxin
topic Chronic migraine
Amitriptyline
Botulinum toxin
description Acesso restrito: Texto completo. p. 463-466
publishDate 2010
dc.date.issued.fl_str_mv 2010
dc.date.accessioned.fl_str_mv 2012-05-03T19:21:48Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.repositorio.ufba.br/ri/handle/ri/5767
dc.identifier.issn.none.fl_str_mv 0303-8467
dc.identifier.number.pt_BR.fl_str_mv v. 112, n. 6
identifier_str_mv 0303-8467
v. 112, n. 6
url http://www.repositorio.ufba.br/ri/handle/ri/5767
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.pt_BR.fl_str_mv DOI: 10.1016/j.clineuro.2010.02.004
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFBA
instname:Universidade Federal da Bahia (UFBA)
instacron:UFBA
instname_str Universidade Federal da Bahia (UFBA)
instacron_str UFBA
institution UFBA
reponame_str Repositório Institucional da UFBA
collection Repositório Institucional da UFBA
bitstream.url.fl_str_mv https://repositorio.ufba.br/bitstream/ri/5767/1/__ac.els-cdn.com_S030384...f27d3c08fc3ed10c3efbf15a99171.pdf
https://repositorio.ufba.br/bitstream/ri/5767/2/license.txt
https://repositorio.ufba.br/bitstream/ri/5767/3/__ac.els-cdn.com_S030384...f27d3c08fc3ed10c3efbf15a99171.pdf.txt
bitstream.checksum.fl_str_mv d7e81783ccc1abefedcc2130a48ec01f
1b89a9a0548218172d7c829f87a0eab9
152139dc1a4ca8b672643bed94a83466
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)
repository.mail.fl_str_mv
_version_ 1801502443898404864

Registros relacionados